SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today reported its financial results for the second quarter and six-months ended June 30, 2019 and provided a business update.
Recent Business Highlights
• Presented initial results from key clinical studies designed to evaluate the performance of Saphyr® against traditional cytogenetics methods at the European Human Genetics Conference. Several posters were presented, including:
- A poster from the team of Alex Hoischen, Ph.D. at Radboud University Medical Center in the Netherlands entitled: “Next generation cytogenetics in medical genetics with high-resolution optical mapping,” where Tuomo Mantere and colleagues described the comparison of Bionano optical mapping on Saphyr with a suite of traditional cytogenetic methods including fluorescence in situ hybridization (FISH), karyotyping and chromosomal microarray (CMA). Additionally, as part of a workshop held at the same conference, Dr. Hoischen provided an up to the minute report on the ongoing study, noting that roughly 20% of the hematologic malignancy cases in the study had been completed and that about 35% of the human genetic disease cases were complete. The authors concluded that Bionano optical mapping with Saphyr identified all clinically reported variants with variant allele fraction greater than 10% in patients tested for hematologic malignancies and similarly that all known aberrations were identified in patients tested for constitutional genetic disorders. The authors further reported that in many cases, the complex pathogenic variants identified by Saphyr proved to be more complex than had been previously known based on an understanding developed with lower resolution methods such as FISH, karyotyping and CMA. The finding of additional complexity implies the potential for Saphyr to be used to further stratify patients in the future, leading to better treatment decisions and patient outcomes.
- In another study, entitled: “Evaluation of the Bionano optical mapping technology as a replacement of conventional cytogenetics in a diagnostic setting,” Charlotte Keith and team from Western General Hospital in Edinburgh, Scotland, compared Bionano optical mapping to karyotyping and CMA on benchmark samples, including those containing balanced translocations and large deletions. In one case, the higher resolution of optical mapping resolved the breakpoint of a translocation to being within a gene, and demonstrated that the translocation truncated the gene, potentially altering the function of the gene. The authors report that the successful proof-of-principle study has cleared the way to a larger validation, which upon successful completion, could potentially enable use of the Bionano Saphyr system in clinical workflows.
- In an oral presentation, Lisanne Vervoort from the Katholieke Universiteit Leuven, Belgium presented a study on DiGeorge syndrome, a syndrome typically affecting infants with symptoms including heart defects, developmental delay and frequent infections. The Leuven team has been able to decode the complex, repetitive region of the genome that is responsible for the disease using Bionano optical mapping as part of a large collaboration. Furthermore, the authors leveraged data from a large population study of 154 human samples from different ethnic groups to determine the ethnic differences in the frequency of these specific genomic structures to potentially explain ethnic variation in the disease.
- In another study, Laila El-Khattabi, Pharm.D., Ph.D. from Hospital Cochin of Paris Descartes University presented results where Saphyr detected a wide variety of balanced and unbalanced chromosomal abnormalities that occur in developmental disorders such as autism and developmental delay, and reproductive disorders such as male infertility and recurrent pregnancy loss, as part of a 30-sample clinical validation initiative. Several balanced translocations detected by Saphyr had been missed by whole genome sequencing analysis. Saphyr showed its ability to detect the clinically relevant variants that otherwise would need to be sought after by a combination of less efficient traditional techniques, such as karyotyping and chromosomal microarrays.
• Appointed Kristiina Vuori, M.D., Ph.D., to its board of directors. Dr. Vuori is recognized for delineating molecular pathways that regulate cancer cell survival, motility, metastasis and drug responsiveness, and her molecular characterization of prolyl hydroxylase helped to enable the formation of FibroGen (NASDAQ: FGEN). Dr. Vuori is President of Sanford Burnham Prebys Medical Discovery Institute (SBP) and serves as Professor of the National Cancer Institute (NCI)-designated Cancer Center at SBP.
“We remain steadfastly focused on our markets as our execution continues to drive interest and build demand. We are pleased to make progress each quarter on our goal of establishing Saphyr as a best-in-class structural variation detection and discovery system,” said Erik Holmlin, Ph.D., CEO of Bionano. “We also continue to add to the body of scientific evidence demonstrating Saphyr to be comparable to the standard of care in cytogenetics but with a more reliable and cost effective workflow.”
Second Quarter Financial Highlights
Total Revenue. Total revenue decreased by $1.2 million, or 35.9%, to $2.2 million for the three months ended June 30, 2019 compared to $3.4 million for the same period in 2018. The decrease in revenue is driven predominantly by a decrease in international sales. Below is a summary of changes for the three months ended June 30, 2019 as compared to the same period in 2018:
- North America revenue decreased by $0.1 million, or 9%;
- EMEIA revenue decreased by $0.5 million, or 51%; and
- Asia Pacific revenue decreased by $0.6 million, or 66%.
Cost of Revenue. Total cost of revenue decreased by $0.3 million, or 14.2%, to $1.6 million for the three months ended June 30, 2019 compared to $1.8 million for the same period in 2018. The decrease was predominantly due to a reduction in the number of instruments and consumables sold.
Operating Expenses. Operating expenses increased by $1.9 million, or 33.5%, to $7.5 million for the three months ended June 30, 2019 compared to $5.6 million for the same period in 2018. The increase was mainly attributed to higher selling, general, and administrative expense which was due to the addition of public company costs as well as the addition of sales and marketing professionals and support personnel to assist with the growth of our worldwide commercial footprint.
Net Loss. Net loss for the three months ended June 30, 2019 was $7.7 million compared to a net loss of $3.3 million for the same period in 2018.
Cash and cash equivalents. At June 30, 2019, the Company had cash and cash equivalents of $15.3 million, compared to cash and cash equivalents of $16.5 million at December 31, 2018.
Conference Call & Webcast Details
The Company will host a conference call and live webcast to discuss its second quarter 2019 financial results and provide an update on business activities. The event will be held today at 4:30 p.m. Eastern Time. Dial-in details are as follows:
| Date: | Thursday, August 8, 2019 | |
| Time: | 4:30 p.m. Eastern Time | |
| Toll Free: | 800-263-0877 | |
| International: | 646-828-8143 | |
| Conference ID: | 2516163 | |
| Webcast: | http://public.viavid.com/index.php?id=135567 |
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay in the Investors section of the Bionano website.
About Bionano Genomics
Bionano is a life sciences instrumentation company in the genome analysis space. Bionano develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and is designed to drive the adoption of digital cytogenetics, which is a more systematic, streamlined and industrialized form of traditional cytogenetics. The Saphyr system comprises an instrument, chip consumables, reagents and a suite of data analysis tools.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Saphyr’s unique ability to comprehensively detect structural variations and identify their human disease associations; the benefits of recent improvements to the Saphyr system, including improved cost effectiveness, speed and ease of use for digital cytogenetics; the benefits of new data and publications, including their validation of Saphyr as the leading digital cytogenetics; and our efforts to execute on our commercial strategy. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks that our sales, revenue, expense and other financial guidance may not be as expected, as well as risks and uncertainties associated with: general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2018 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
Contacts
Bionano Contact:
Mike Ward, CFO
Bionano Genomics, Inc.
+1 (858) 888-7600
mward@bionanogenomics.com
Bionano Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 535-7742
arr@lifesciadvisors.com
Media Contact:
Kirsten Thomas
The Ruth Group
+1 (508) 280-6592
kthomas@theruthgroup.com
Financial tables follow
Bionano Genomics, Inc.
Consolidated Statements of Operations
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2019 | 2018 | 2019 | 2018 | ||||||||||||
| Revenue: | |||||||||||||||
| Product revenue | $ | 2,020,398 | $ | 3,256,023 | $ | 3,707,984 | $ | 4,918,245 | |||||||
| Other revenue | 154,237 | 133,986 | 319,397 | 240,249 | |||||||||||
| Total revenue | 2,174,635 | 3,390,009 | 4,027,381 | 5,158,494 | |||||||||||
| Cost of revenue: | |||||||||||||||
| Cost of product revenue | 1,525,334 | 1,803,461 | 2,644,885 | 2,644,043 | |||||||||||
| Cost of other revenue | 29,912 | 9,969 | 57,403 | 10,836 | |||||||||||
| Total cost of revenue | 1,555,246 | 1,813,430 | 2,702,288 | 2,654,879 | |||||||||||
| Operating expense: | |||||||||||||||
| Research and development | 2,407,692 | 2,098,826 | 4,507,803 | 4,465,919 | |||||||||||
| Selling, general and administrative | 5,056,005 | 3,489,974 | 9,846,607 | 6,385,378 | |||||||||||
| Total operating expense | 7,463,697 | 5,588,800 | 14,354,410 | 10,851,297 | |||||||||||
| Loss from operations | (6,844,308 | ) | (4,012,221 | ) | (13,029,317 | ) | (8,347,682 | ) | |||||||
| Other income (expense): | |||||||||||||||
| Interest expense | (565,888 | ) | (407,635 | ) | (838,392 | ) | (709,616 | ) | |||||||
| Change in fair value of preferred stock warrants and expirations | — | 1,517,723 | — | 2,470,921 | |||||||||||
| Loss on debt extinguishment | — | (342,164 | ) | (921,496 | ) | (342,164 | ) | ||||||||
| Other expense | (249,884 | ) | (61,673 | ) | (718,132 | ) | (221,015 | ) | |||||||
| Total other income (expense) | (815,772 | ) | 706,251 | (2,478,020 | ) | 1,198,126 | |||||||||
| Loss before income taxes | (7,660,080 | ) | (3,305,970 | ) | (15,507,337 | ) | (7,149,556 | ) | |||||||
| Provision for income taxes | (4,486 | ) | (5,506 | ) | (8,972 | ) | (9,282 | ) | |||||||
| Net loss | $ | (7,664,566 | ) | $ | (3,311,476 | ) | $ | (15,516,309 | ) | $ | (7,158,838 | ) | |||
Bionano Genomics, Inc.
Consolidated Balance Sheets
| June 30, 2019 | December 31, 2018 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 15,294,526 | $ | 16,522,729 | |||
| Accounts receivable, net | 4,983,510 | 4,514,333 | |||||
| Inventory | 3,022,090 | 1,068,557 | |||||
| Prepaid expenses and other current assets | 631,853 | 919,500 | |||||
| Total current assets | 23,931,979 | 23,025,119 | |||||
| Property and equipment, net | 1,278,889 | 1,777,302 | |||||
| Total assets | $ | 25,210,868 | $ | 24,802,421 | |||
| Liabilities and stockholders’ equity (deficit) | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 3,617,836 | $ | 1,351,736 | |||
| Accrued expenses | 2,702,015 | 2,900,129 | |||||
| Deferred revenue | 421,342 | 270,998 | |||||
| Line of credit | 799,815 | — | |||||
| Total current liabilities | 7,541,008 | 4,522,863 | |||||
| Long-term debt | 18,621,696 | 9,029,374 | |||||
| Long-term deferred revenue | 219,202 | 304,467 | |||||
| Other non-current liabilities | 173,772 | 808,366 | |||||
| Total liabilities | 26,555,678 | 14,665,070 | |||||
| Total stockholders’ equity (deficit) | (1,344,810 | ) | 10,137,351 | ||||
| Total liabilities and stockholders’ equity (deficit) | $ | 25,210,868 | $ | 24,802,421 | |||